Loading DNA
Loading EPIC...
Skip to main content
EPIC Logo Left
EPIC Logo Right

Epigenetic Programmable Intervention and Control

Beyond Hardware - Unlocking the Genomic Operating System

Scroll to explore

We present dCas9-dam - our fusion protein with gRNA capable of making precise epigenetic edits on the genome.

What is EPIC?

EPIC is a CRISPR-based toolkit that converts bacterial DNA methylation from a global, untargeted process into a programmable, site-specific regulatory tool.

Why this is not "just another expression regulating tool"

Gene expression control in bacteria is already well-established, and EPIC does not aim to outperform existing tuning methods. Instead, it introduces an entirely new dimension to genetic engineering, one that leverages epigenetic memory to achieve programmable and heritable control over expression.

The Guide:

Guide RNA sequences direct the EPIC system to any specific genomic site.

The Rewrite:

The dCas9-Dam complex methylates the targeted sequence.

The Result:

This targeted methylation rewrites the gene expression: selectively activating or silencing the gene with unrivaled precision.

Precise Targeting

Our engineered dCas9-Dam system provides a novel pipeline for DNA methylation targeting.

DNA Strand
Protein-DNA Complex

Controlled Methylation

The fusion protein enables selective epigenetic modification without altering the DNA sequence.

Potential Applications

🏭

Biomanufacturing

Precise epigenetic modifications for therapeutic applications, enabling targeted gene expression control without permanent DNA alterations for treating genetic disorders.

🧠

Epigenetic Memory Systems & Biosensors

Single-trigger “lock-in” circuits translate transient environmental signals into lasting expression states, forming the basis for self-sustaining biosensors and adaptive bioprocess control.

💊

Therapeutics

Targeted methylation and demethylation can reversibly modulate disease-linked genes, offering precision control for regenerative medicine, metabolic reprogramming, and next-generation cell-based therapies.